Hong Kong-based life science investment firm Ally Bridge Group last Wednesday announced that it has led an over-subscribed US$65 million funding round in Pulmonx Corporation, a company that specializes in diagnostic and therapeutic pulmonary device technologies.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?